Novartis AG (NVS) Q4 2024 Earnings Call Transcript
Novartis AG (NVS) Q4 2024 Earnings Call Transcript
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Swiss pharma giant Novartis posts better-than-expected fourth-quarter sales
Swiss pharmaceutical giant Novartis on Friday reported better-than-expected sales in the fourth quarter, but falling short of its own guidance over the full-year stretch. Fourth-quarter net sales rose 16% on a constant currency basis to $13.2 billion, compared to the $12.795 billion estimated by analysts in an LSEG poll.
Novartis CEO says U.S. exit from global health programmes to affect millions
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming millions of people worldwide.
Novartis beats consensus on Q4 earnings
Novartis on Friday posted quarterly adjusted net income well above analyst estimates on higher drug revenues.
Novartis to Report Q4 Earnings: What's in the Offing?
NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the fourth quarter.
US appeals court lifts pause on generic version of Novartis' Entresto
Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' blockbuster heart-failure drug Entresto after a U.S. appeals court ended a temporary pause on MSN's launch.
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
On Thursday, Outlook Therapeutics, Inc. OTLK completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degeneration (wet AMD) patients.
Novartis loses emergency bid to block Entresto generic in US
A Washington, D.C. federal judge on Wednesday refused Novartis' eleventh-hour bid to block drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart-failure drug Entresto.
Novartis AG (NVS) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Novartis AG (NYSE:NVS ) J.P. Morgan 43rd Annual Healthcare Conference January 14, 2025 12:00 PM ET Company Participants Vas Narasimhan - Chief Executive Officer Conference Call Participants Richard Vosser - J.P.
Novartis CEO: We need to get Europe to pay its fair share
Novartis CEO Vas Narasimhan discusses the pricing of drugs in the U.S. compared to other countries.
Novartis CEO Vas Narasimhan: Expect solid growth this year top and bottom line
CNBC's Angelica Peebles and Novartis CEO Vas Narasimhan join 'Squawk Box' to discuss the company's drug pipeline, managing patent cliffs, drug pricing under Trump, and more.
